DDInter1251 DDInter1676
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mycophenolate mofetil {u} (Compound) resembles {v} (Compound) Mycophenolic acid
Mycophenolate mofetil {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) UGT1A10
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) FAM63A
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) HJURP
Mycophenolate mofetil {u} (Compound) causes {v} (Side Effect) Furunculosis
Mycophenolate mofetil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acyclovir
Mycophenolate mofetil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Mycophenolate mofetil (Compound) treats systemic lupus erythematosus (Disease)
Mycophenolate mofetil (Compound) binds UGT1A10 (Gene)
Mycophenolate mofetil (Compound) upregulates FAM63A (Gene)
Mycophenolate mofetil (Compound) downregulates HJURP (Gene)
Mycophenolate mofetil (Compound) causes Furunculosis (Side Effect)
Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Acyclovir
Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Theophylline
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Anakinra